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Background: Catgut implantation at acupoints has been used in China to treat allergic rhinitis (AR) for a long time.
However, its efficacy and safety in the treatment of AR is controversial due to the poor quality of the clinical trial of
this therapy. This study aims to identify whether catgut implantation at acupoints is indeed an effective and safe
treatment for patients with persistent or intermittent allergic rhinitis (PER or IAR) by comparing with sham catgut
implantation treatment.
Methods and design: This study compares real versus sham catgut implantation at acupoints in 242 patients with
a history of PER or IAR and with a positive skin prick test (SPT). The trial will be conducted in the Teaching Hospital
of Chengdu University of Traditional Chinese Medicine. In the study, patients will be randomly assigned by
computer-generated randomization list into two groups and assessed prior to treatment. Then, they will receive
two sessions of treatments (once per 2 weeks) for 4 consecutive weeks and have a follow-up phase of 12 weeks.
The administration of catgut implantation (or sham-control) at acupoints follows the guidelines for clinical research
on acupuncture (WHO Regional Publication, Western Pacific Series No.15, 1995), and is performed double-blindly by
a well-trained physician in acupuncture. The main outcome measures include the primary and secondary indicators.
Primary indicators are subjective symptoms scores evaluated by visual analogue scales (VAS) and Rhinoconjunctivitis
Quality of Life Questionnaires (RQLQ). The secondary indicators are the results of laboratory examinations, such as
serum allergen-specific IgE, nasal inflammatory cells counts (mast cells, eosinophils, and T cells) and nitric oxide
concentration in nasal excretion. The use of anti-allergic medication will also be recorded as one of the secondary
indicators. Furthermore, adverse events will be recorded and analyzed. If any participants withdraw from the trial,
intention-to-treat analysis (ITT) and per-protocol (PP) analysis will be performed.
Discussion: The important features of this trial include the randomization procedures, large sample, and a
standardized protocol of catgut implantation at acupoints. This trial will be the first study with a high evidence level
in China in order to assess the efficacy and safety of catgut implantation at acupoints in treatment of AR following
a randomized, double-blind sham-controlled method.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-12002191
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Allergic rhinitis (AR) is an IgE-mediated immune disease
triggered by allergens with symptoms of nasal obstruc-
tion, itching, watery rhinorrhea, and sneezing. AR has
become a major health problem worldwide. It has been
estimated by the ARIA (Allergic Rhinitis and its Impact
on Asthma) 2008 document that over 600 million patients
from all countries, in all ethnic groups, and of all ages
suffer from AR [1]. In China, the prevalence of allergic
rhinitis has increased to 24.6% in 2007 according to the
epidemiological study in 11 major cities in China [2]. Fur-
thermore, there is a well-documented relationship existing
between nasal allergy and asthma. The prevalence of
asthma in patients with rhinitis could reach up to 40%,
and the majority of patients with asthma experience rhin-
itis symptoms [1].
AR causes an impairment on the quality of life (QOL)
of patients and results in significant healthcare costs. As
an available and affordable treatment choice, acupunc-
ture has been accepted as a therapeutic option for reliev-
ing symptoms of AR in China and other countries [3-7].
Catgut implantation at acupoints is a subtype of acu-
puncture, which can be embedded in the acupoint by
using a special needle. A period of time may be needed
for the catgut to be completely absorbed by the tissue.Figure 1 Trial flowchart (*blindly assessed).Therapeutic effects can be achieved by continuing stimu-
lation caused by the catgut at the acupoint. Therefore, cat-
gut implantation at acupoint may be effective in treating
some chronic disease such as AR.
Although catgut implantation at acupoint has been used
in treating diseases for a few thousand years in China,
there have been very few clinical trials which have been
strictly designed to verify the efficacy and safety of this
treatment for AR [8]. It is indeed necessary to obtain high
level of evidences for catgut implantation at acupoints in
the treatment of AR (Figure 1).
We have recently conducted a pilot clinical trial to
compare the efficiency of catgut implantation at acu-
point with triamcinnone acetonide nasal spray in the
treatment of AR. The results suggested that therapeutic
efficacies were similar between these two groups at the
end of the 4-week period of treatment. However, after
3 months of follow-up, the recurrence rate of AR was
much lower in the catgut implantation group than in
the intranasal glucocorticoid one. Furthermore, symptom-
free days were longer in the catgut implantation group.
Based on this pilot study, we wish to design a
randomized, double-blind, large-scale clinical trial to
compare the effectiveness and safety of real catgut im-
plantation at acupoints with those of the sham one for
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been approved by Sichuan Regional Ethics Review Com-
mittee on Traditional Chinese Medicine with an ethics
approval number of 2012KL-002. The work reported in
this article is registered with an identifier (ChiCTR-
TRC-12002191) by Chinese Clinical Trial Registry.
Methods and design
Study design
This study will be a double-blind, randomized, sham-
controlled trial conducted in the Department of
Otorhinolaryngology-head and neck surgery, Teaching
Hospital of Chengdu University of T.C.M., China. This
study includes the following time points: a run-in period
of 4 weeks after screening, a treatment period of 4 weeks,
and a follow-up period of 12 weeks. The total study period
will be 20 weeks. At the screening visit, medical history
especially in relation to AR and other allergic diseases
will be asked and recorded by a study physician based
on a systemically designed questionnaire. Patients who
satisfy the inclusion criteria will be recruited into the
run-in period. After randomization, patients will be
blindly assigned to either the real catgut implantation at
the acupoints group or the sham group (controls). All
patients will receive two treatments over a period of
4 weeks. Chlorphenyramine will be used as a rescue
medication if the patients present with untolerable AR
symptoms. At the same time, patients should complete
visual analogue scales (VAS) [9] and Rhinoconjunctivitis
Quality of Life Questionnaires (RQLQ) [10,11] before
randomization, at the end of treatment, during and after
the follow-up period, respectively. Meanwhile, inflamma-
tory cells and mediators in nasal secretions will also be
measured at these three visits. Outcome measurements
will be assessed by evaluating the efficacy and safety of
catgut implantation at acupoints in the treatment of AR.
The design of this study followed the guidelines of the
Helsinki Declaration (Version Edinburgh 2000) and was
approved by Sichuan Regional Ethics Review Committee
on Traditional Chinese Medicine (TCM). Informed con-
sent are to be obtained from all the study patients. Before
signing the consent, all patients will be given enough time
to decide whether to participate in the trial. Other treat-
ment options instead of catgut implantation at acupoints
will be available for those who are unwilling to be
recruited in the study.
Randomization and blinding
Random number of allocation sequence will be generated
by computer (using SPSS 15.0 statistical software pack-
age). A computer program that allows the patients to be
assigned to either the real catgut implantation group or
the sham-controlled group in a 1:1 ratio will be used. The
random numbers will then be sealed in opaque envelopes.Participants who meet the inclusion criteria will be
asked to pickup one of the envelopes. At the same time,
the participants’ random numbers and the corresponding
randomization information which includes the participant’s
name in a pinyin format, the participant’s numerical birth-
day, and gender will be recorded in a random allocation
table in duplicate and sealed in opaque envelopes, respect-
ively. These opaque envelopes should be preserved separ-
ately by the principal investigator and the primary sponsor.
The envelopes must be kept intact until cease blinding.
The administrator who is in charge of random allocation
should not participate in enrolling patients. Participants,
researchers, and study physicians who interview and recruit
patients are blinded to the group assignments. The
acupuncturists are responsible for treatment proceedings
of both groups, and therefore it would be difficult to blind
the acupuncturists during the study. However, they will
not communicate with the study patients nor participate
in the assessment of study outcomes.
The two randomized groups will be named A or B in
the medical records and case report forms which are not
directly link to the treatment. All information will be
lockedout and saved in a database before statistical ana-
lysis is performed. After statistical analysis, the blind
exposure will be provided. The two opaque envelopes
which contain the random allocation tables should be
unsealed by the principal investigator and the primary
sponsor simultaneously to clarify which group is the
real treatment group or the sham-controlled group.Inclusion criteria
Patients who will be recruited in this study should meet
the inclusion criteria including:
(1) aged between 18 and 70 years
(2) not be taking part in any other clinical trials
(3) having no previous experience of catgut
implantation at acupoints
(4) provide written informed consent
(5) presenting with typical symptoms of AR, such as
rhinorrhoa, sneezing, nasal obstruction, and
pruritus. These symptoms should last >1 h on most
days. Some patients may have ocular symptoms due
to outdoor allergens
(6) with positive skin prick tests performed by trained
health professionals
A standardized vaccine (Alutard SQ, ALK- Abelló,
Denmark) will be used in the prick test. Oral H1-
antihistamines are not permitted before skin test. Skin
prick tests should be read at the peak of their reaction
by measuring the wheal and the flare approximately
15 min after the performance of the test.
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Patients with any of the following conditions will be
excluded:
(1) pregnant women or women who have been trying
to get pregnant in the last 6 months, or women
who are lactating
(2) patients who are receiving immune therapy
(3) patients with other allergic diseases, such as
bronchial asthma or allergic purpura
(4) patients with nasal polyposis
(5) heterologous protein allergy
(6) patients with other organic disorders, such as AIDS,
vascular malformation, hypertension, hematologic
diseases, diabetes mellitus, malignant tumor, and
mental disorders
Withdrawal from the study
Study patients will be allowed or be asked to withdraw
from the study if:
(1) they have been included in the trial but would not
subject to the assigned treatment for varies reasons
at any of the stages of the trial
(2) severe adverse events occur that necessitate
withdraw of patients from the trial




In China, most of the patients with symptoms of AR will
present at the otorhinolaryngology clinics. It is advisable
that all physicians in our department should be familiar
with the study inclusion and exclusion criteria and refer
the appropriate patients to the PI or study physicians.
Then the screening evaluations will be conducted and
the information of the patients will be recorded. Patients
who satisfy the inclusion criteria and are willing to par-
ticipate in the trial will sign on the written informed
consent. Then they will be randomized into either of the
study groups and introduced to the acupuncturists.
Advertisements
Television and newspaper advertisements will be on dis-
play. Printed recruitment posters will also be pasted in
the hospital and the university campus.
Interventions
Participants will receive real or sham catgut implantation
at acupoints once per 2 weeks. Each patient will have
4 treatment weeks and 12 weeks of follow-up. The
interventions are designed according to the documen-
tary records in ancient books and in recent TraditionalChinese Medicine journals. The protocol is developed
in consensus with Chinese acupuncturists and acupunc-
ture experts, and is consistent with both the STRICTA
(Standards for Reporting Interventions in Controlled
Trials of Acupuncture) guidelines for the performance
of acupuncture studies [12] and the guidelines for
clinical research on acupuncture (WHO Regional Pub-
lication, Western Pacific Series No.15, 1995). In our
pilot study, five acupoints were used for catgut im-
plantation and the efficacy was similar between the
catgut implantation in the acupoints group and the
intranasal glucocorticosteroids group. In this trial, the
same acupoints will be chosen in both the real and
sham treatments. All the treatments will be performed
by the same registered acupuncturists to ensure par-
ticipant blinding and consistency of treatment.
Rationale for the selection of acupoints
For the first 2 weeks of treatment, three acupoints are
to be used for each patient. They are Yingxiang (LI20),
Yintang(EX-HN3), and Hegu(LI4). For the second 2 weeks
of treatment, Zusanli(ST36) and Quchi(LI11) will be
chosen (Figure 2).
The traditional acupuncture theories state that AR is
in close correlation with the Taiyin lung meridian of
hand and Yangming large intestine meridian of hand.
Therefore, it is reasonable that the acupoints corre-
sponding to the lung meridian and the large intestine
meridian would be the most effective acupoints in treating
AR. Furthermore, the traditional acupuncture theory
maintains that special points convey special therapeutic
effects. Thus, the most frequently used specific acupoints
for these two meridians would be selected in this trial
according to a previous review of ancient and modern
literature.
In traditional Chinese medicine, the nose is an orifice
with lucid Yang. Yingxiang and Yintang are on the median
line of face. Lucid Yang is confluent at these acupoints.
These two acupoints plays an important role in clearing
nasal passage. In addition, Yingxiang is considered a spe-
cific point on Yangming large intestine meridian of hand.
Hegu is the source-point of the large intestine meridian.
Based on the theory of the lung and the large intestine
being interior-exteriorly related, Yingxiang and Hegu are
important acupoints for facial features. Yintang is an
extraordinary point. The three acupoints could be used to-
gether for improving lung air (qi) deficiency syndrome. In
our previous trial, it has been suggested that symptoms of
AR could be effectively alleviated by embedding catgut at
these three acupoints.
Zusanli (ST36) and Quchi(LI11) are sea points of
Yangming large intestine meridian of hand and Yangming
stomach meridian of foot. The ancient Chinese believed
that Yangming is a meridian abundant of blood and Qi
Figure 2 Locations of acupoints (for both real treatment group and sham-controlled group). Yintang(EX-HN3), yingxiang (LI20),
and Zusanli (ST36) are chosen in the first two weeks of treatment. Hegu(LI4) and Quchi (LI11) will be punctured in the second two weeks
of treatment.
Li et al. Trials 2013, 14:12 Page 5 of 8
http://www.trialsjournal.com/content/14/1/12and is the acquired foundation. Zusanli and Quchi will be
used to fortify the spleen and replenish lung qi. By reinfor-
cing earth to generate metal and by regulating asthenia-
cold in the remission stage of AR, recurrence rate of this
disease might be reduced.
Sham-controlled group
In the control group, the same acupoints are to be
punctured with the same acupuncture needles and same
length and angle according to standard techniques. The
only difference between these two groups is that catgut
would not be embedded into the acupoints in the sham-
controlled group. Because of mild swollen tissue at
acupoints immediately after puncture and lack of previous
experiences for this therapy, the patients will not know
whether catgut has been embedded into the acupoints. To
ensure the blinding manner, acupuncturists are instructed
not to communicate with the participants of whole treat-
ment procedures.
Standard protocol for catgut implantation at acupoints
Only pre-sterilized disposable needles (9#, Hanjiang
Guoxiang Medical Appliance Factory, Yangzhou, China)
and catguts (000, Pudong Jinhuan Medical Products Co.
Lit, Shanghai, China)are used in the trial. For Yintang
(EX-HN3), the needle is to be inserted with a depth of
1.0 cm, downward to the nose in a horizontal direction
with respect to the shin. For Yingxiang (IL20), theTable 1 Acupoints and manipulation for both real and sham
Time Acupoints Angle and direct
First week of treatment Yintang(EX-HN3)(unilateral) Downward to the
Yingxiang(LI20)(both) In an oblique dire
with respect to th
Hegu(LI4)(both) In perpendicular d
Second week of treatment Zusanli(ST36) In perpendicular d
Quchi(IL11) (both) In perpendicular dpenetration is 2.0 cm, in an oblique direction along the
nasolabial sulcus towards the root of nose with respect
to the skin. For Hegu, Zusanli, and Quchi, the penetra-
tion is 2.5 cm, in perpendicular direction with respect
to the skin (Table 1). Twirling, lifting, and thrusting
of the needle do not need to be performed. Both
groups will receive one session of catgut implantation
every 2 weeks for 4 weeks. Subjects will be advised to
lie on a supine position. Pulse rate, blood pressure, and
oxygen saturation are to be monitored routinely during
the procedure as a precautionary measure. In both groups,
pre-injection swabs with 75% alcohol and dry sterile cot-
ton wool are to be used when withdrawing the needles.
Before the puncture, it is advised to inject 0.5% Lidocaine
of about 0.2 to 0.4 mL for each acupoint to alleviate the
pain caused by inserting the needle. After treatment, the
skin of the acupoints is prohibited to touch water or any
cosmetics for 3 days.
The needle used for catgut implantation is similar to a
kind of trocar. It is made up of two parts: the internal
stylet and the external cannula with sharp pinhead
which assures the cannula could puncture into the skin
(Figure 3). In real catgut embedding, the internal stylet
should be withdrawn from the cannula for about 1.5 cm
at first. Then a catgut with the length of 2 to 3 mm will
be put into the cannula from the side of pinhead. When
the needle has been inserted into the acupoints with the
correct depth, the catgut will be pushed into the tissuecatgut implantation group
ion Depth (cm)
nose in a horizontal direction with respect to the shin 1.0
ction along the nasolabial sulcus towards the root of nose
e skin
2.0
irection with respect to the skin 2.5
irection with respect to the skin 2.5
irection with respect to the skin 2.5
Figure 3 Needle for catgut implantation at acupoints.
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whole therapeutic procedure is the same as the real
group except that the catgut is not present in the can-
nula. Patients in the control group will receive only the
stimulus of needling but not of the catgut implantation.
All real and sham catgut implantation are to be performed
by the same acupuncturist consistently throughout the
study. The acupuncturists should have undergone at least
8 years of acupuncture training and be qualified TCM
doctors.
In both groups, patients are permitted to use chlor-
phenyramine when needed. The use of chlorphenyramine
(dosage, frequency, and period of treatment) will be
recorded as relief medicine scores.
Outcome measurements
Primary outcome
The primary outcome measures will be the severity of
the AR symptoms assessed by (VAS) [9] and the RQLQ
[10,11]. In VAS, the severity of the combination of the
nasal symptoms will be subjectively rated by the study
patients on the scale. The severity of symptoms can be
divided into mild, moderate, or severe based on the total
severity VAS score (0 to 10 cm: mild, VAS 0–3; moder-
ate, VAS 3.1-7; severe, VAS 7.1-10). VAS scores will be
recorded every 2 weeks during the whole trial. Influence
of AR on QOL will be measured by questionnaire every
4 weeks: at baseline, at the end of treatment, during the
follow-up period, and at the end of follow-up period
(a total of five times). Both the scores of VAS and RQLQ
questionnaire will be blindly assessed.
Secondary outcome
Secondary outcome measures include relief medication
scores, serum allergen-specific IgE, nasal inflammatory
cells counts (mast cells, eosinophils, and T cells), the
level of nitric oxide concentration in nasal secretion, and
side effects.
Patients will be asked to complete diaries in the base-
line and every 2 weeks after randomization. In thediaries, they will document the intensity, frequency,
length, and symptoms in each AR attack. The patients
will also record if H1-blocker (chlorphenyramine) has
been taken during the whole treatment periods, includ-
ing the dosage and time of medication. In addition, ad-
verse events (for example, numbness, hematoma, local
infection of the acupuncture sites, headache, fainting,
and serious pain) will also be recorded during the treat-
ment and follow-up phases.Patient safety
Before randomization, patients will be asked to undergo
routine tests of blood, urine, and stool, as well as electro-
cardiogram (ECG), liver function, hepatitis serology, serum
antibody of AIDS, blood glucose, and kidney functions
in order to exclude any related serious illness. The
results of these tests will allow the assessment of risks
associated with catgut implantation at acupoints. If any
adverse effect occurs during the trial, patients will con-
tact with the principal investigator as soon as possible
to get proper medical treatment.Quality control
All acupuncturists are required to receive special training,
including the technique for catgut implantation and the
way to deal with adverse events. The acupuncturists
should also learn how to use the randomization method in
order to communicate with patients and to keep them
blind to the treatment throughout the trial. Only those
who have completed the required training and have passed
all necessary examinations will be recruited for this trial.
In order to maintain quality of this trial, all outcome
assessments will be blinded. In addition, all researchers
must understand the purpose and design of this trial.
Audits will be conducted regularly on compliance with
standard operation procedures every week. Report of
audits should be presented to the chief monitor. If patients
withdraw from the trial either in the treatment period or
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the rate should be analyzed in statistics.
Statistical analysis
In our preliminary study to compare the efficacy of cat-
gut implantation at acupoints with intranasal gluco-
corticoid, it was suggested that efficiency was 93.75% in
the catgut implantation group and 96.88% in the control
group. In this study, we anticipate an improvement of no
less than 15% after real catgut implantation at acupoints.
However, there are no previous data regarding the VAS or
RQLQ scores for the treatment of AR with catgut im-
plantation at acupoints. Considering participants recruited
in the two groups are in a 1:1 ratio, the following formula
was used to estimate sample size [13]:
n1 ¼ n2 ¼ Zα
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2πc 1 πcð Þ
p þ Zβ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃπ1 1 π1ð Þ þ π2 1 π2ð Þp
π1  π2
" #2
In the formula: n1, n2 represents the sample size of
each group. π1, π2 is the overall rate of each sample, respec-
tively. πc = (π1+π2)/2, α=0.05, Z0.05 = 1,96,β=0.10,Z0.10 =
1.282. Statistical analysis will be performed using a 5% sig-
nificance and 90% power, resulting in an estimated 121
patients per group.
To test our hypothesis, the first step is to assess the
baseline characteristics of two groups using an unpaired
t test or x2 testes. The second step is to compare the
efficacy of real catgut implantation with the sham one,
including the primary and secondary outcomes using
two-sample t test. If there is any case lost in follow-up
phase or withdrawn from the trial, the causes of with-
drawal should be clarified. The intention-to-treat ana-
lysis (ITT) and per-protocol (PP) analysis should be
conducted to test whether the result of this trial is cred-
ible. For relief medication, within-group as well as
between-group comparisons of scores are to be made.
Data will be analyzed using the Statistical Package for
the Social Sciences software, version 15.0 for Windows
(SPSS Inc., Chicago, IL, USA). Data are presented as
mean and 95% confidence intervals (CI). The statistical
analysis will be performed in a blinded manner by quali-
fied statisticians.
Discussion
Based on the theory and practice of TCM and acupunc-
ture, it indicates that acupuncture is effective in treating
some chronic diseases. Acupuncture has proven to be
useful in relieving symptoms of AR. In Western coun-
tries, acupuncture has been gradually accepted based on
evidence from randomized, double-blind clinical trials in
the treatment of AR.
Besides conventional puncture and moxibustion, acu-
puncture can be performed by such as acupoint application,auricular acupoint pressing, and catgut implantation at
acupoints. Catgut implantation at acupoints can extend the
sensation of needling because of the persistent stimulus to
acupoints by embedding catgut. Furthermore, catgut
implantation has an effect which is similar to pricking
blood therapy. Hence, it was found to be able to dredge
the channels and invigorate the pulse, and regulate qi
and blood. Catgut implantation at acupoints has a par-
ticular therapeutic effect for some chronic diseases.
In our pilot study, the efficacy and safety of catgut
implantation at acupoints were compared with the
intranasal glucocorticoid treatment. It has been shown
that the clinical efficacy was similar in the two groups
and catgut implantation at acupoints were well tolerated
by participants. However, the limitations of this pilot study
are due to a small sample size (only 64 subjects were
enrolled) and it was not performed in a blinded man-
ner. To our knowledge, there has been no other
randomized, double-blinded controlled trial of catgut
implantation at acupoints for AR [14-16]. In order to
obtain more useful clinical evidence for this therapy,
we have designed this trial following the principles of
good clinical trials.
In the literature, a technique in which needles are
inserted shallowly at locations of 1 to 2 cm away from
the defined acupoints is a common sham control for
clinical study for acupuncture. In our study, the sham
treatment is to insert needles at the same acupoints with
the same acupuncture manipulation but without catgut
embedding. In order to ensure the efficacy and safety of
the treatment, acupuncturists should undergo special
training and be qualified by having sufficient knowledge,
special technique, and good experience in acupuncture. In
addition, it is performed in a design of double-blind and
randomized manner. All study patients will be informed
by potential treatment of either real catgut implantation at
acupoints or the sham one. The sham treatment may have
unspecific physiologic effects of needling or just have
placebo effects. In this study, a short acting antihistamine
is permitted as a rescue medication. All patients are
required to keep a record of the usage of drugs and relief
medication scores will be calculated.
In conclusion, the aim of this study is to investigate the
efficacy and safety of catgut implantation at acupoints for
treatment of AR. It will be the first time that good clinical
evidence of this treatment in AR will be obtained.
Trial status
The recruitment of patients started June 1,2012, and it is
expected that by March 31, 2013 the required sample
size will be reached.
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